Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia

European Journal of Immunology

Volumn 45, Issue 7, 2015, Pages 1980-1990

  Rolf, Nina ^a   Kariminia, Amina ^a   Ivison, Sabine ^a   Reid, Gregor S ^a   Schultz, Kirk R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Caspase 8 mediated apoptotic cell death; CD40; Heterodimer specific TLR2 stimulation; Pediatric acute lymphoblastic leukemia; Signaling kinetics

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE 8; HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; VINCRISTINE; CD40 ANTIGEN; LIPOPEPTIDE; PAM(3)CSK(4) PEPTIDE; TLR2 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL SPECIFICITY; CHEMOSENSITIZATION; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION; TUMOR CELL; AGONISTS; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD40; APOPTOSIS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LIPOPEPTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 84937191666     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444874     Document Type: Article

References (92)

1. Decker, W. K. and Safdar, A., Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 2009. 20: 271-281.
2. Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C. and Tartour, E. et al., Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012. 1: 699-716.
3. Kaczanowska, S., Joseph, A. M. and Davila, E., TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 2013. 93: 847-863.
4. Hobohm, U., Stanford, J. L. and Grange, J. M., Pathogen-associated molecular pattern in cancer immunotherapy. Crit. Rev. Immunol. 2008. 28: 95-107.
5. Rakoff-Nahoum, S. and Medzhitov, R., Toll-like receptors and cancer. Nat. Rev. Cancer. 2009. 9: 57-63.
6. Janeway, C. A. and Medzhitov, R., Innate immune recognition. Annu. Rev. Immunol. 2002. 20: 197-216.
7. Matzinger, P., The danger model: a renewed sense of self. Science 2002. 296: 301-305.
8. Iwasaki, A. and Medzhitov, R., Regulation of adaptive immunity by the innate immune system. Science 2010. 327: 291-295.
9. Kawai, T. and Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010. 11: 373-384.
10. Schenten, D. and Medzhitov, R., The control of adaptive immune responses by the innate immune system. Adv. Immunol. 2011. 109: 87-124.
11. Goutagny, N., Estornes, Y., Hasan, U., Lebecque, S. and Caux, C., Targeting pattern recognition receptors in cancer immunotherapy. Target. Oncol. 2012. 7: 29-54.
12. Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G. and Galluzzi, L., Trial watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013. 2: e25238.
13. Maywald, O., Buchheidt, D., Bergmann, J., Schoch, C., Ludwig, W.-D., Reiter, A., Hastka, J. et al., Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature. Ann. Hematol. 2004. 83: 189-194.
14. Chen, R.-L. and Chuang, S.-S., Transient spontaneous remission after tumor lysis syndrome triggered by a severe pulmonary infection in an adolescent boy with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 2009. 31: 76-79.
15. Bierman, H. R., Crile, D. M., Dod, K. S., Kelly, K. H., Petrakis, N. L., White, L. P. and Shimkin, M. B., Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 1953. 6: 591-605.
16. Pelner, L., Fowler, G. A. and Nauts, H. C., Effects of concurrent infections and their toxins on the course of leukemia. Acta Med. Scand. Suppl. 1958. 338: 1-47.
17. Dock, G., The influence of complicating diseases upon leukemia. Am. J. Med. Sci. 1904. 127: 563-592.
18. Hirshberg, C. and O'Regan, B., Infection related remission. In Spontaneous remission: an annotated bibliography. Institute of Noetic Sciences, Petaluma, CA, USA, 1993, pp. 578-646.
19. Kleef, R., Jonas, W. B., Knogler, W. and Stenzinger, W., Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation 2001. 9: 55-64.
20. Hobohm, U., Fever and cancer in perspective. Cancer Immunol. Immunother. 2001. 50: 391-396.
21. Dunne, A., Marshall, N. A. and Mills, K. H. G., TLR based therapeutics. Curr. Opin. Pharmacol. 2011. 11: 404-411.
22. Reid, G. S. D., She, K., Terrett, L., Food, M. R., Trudeau, J. D. and Schultz, K. R., CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood 2005. 105: 3641-3647.
23. Fujii, H., Trudeau, J. D., Teachey, D. T., Fish, J. D., Grupp, S. A., Schultz, K. R. and Reid, G. S. D., In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood 2007. 109: 2008-2013.
24. Zähringer, U., Lindner, B., Inamura, S., Heine, H. and Alexander, C., TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 2008. 213: 205-224.
25. Ozinsky, A., Underhill, D. M., Fontenot, J. D., Hajjar, A. M., Smith, K. D., Wilson, C. B., Schroeder, L. et al., The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl. Acad. Sci. USA 2000. 97: 13766-13771.
26. Takeuchi, O., Sato, S., Horiuchi, T., Hoshino, K., Takeda, K., Dong, Z., Modlin, R. L. et al., Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 2002. 169: 10-14.
27. Long, E. M., Millen, B., Kubes, P. and Robbins, S. M., Lipoteichoic acid induces unique inflammatory responses when compared to other toll-like receptor 2 ligands. PLoS One 2009. 4: e5601.
28. Depaolo, R. W., Tang, F., Kim, I., Han, M., Levin, N., Ciletti, N., Lin, A. et al., Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Cell Host Microbe. 2008. 4: 350-361.
29. Li, J., Lee, D. S. W. and Madrenas, J., Evolving bacterial envelopes and plasticity of TLR2-dependent responses: basic research and translational opportunities. Front. Immunol. 2013. 4: 347.
30. Bekeredjian-Ding, I. and Jego, G., Toll-like receptors-sentries in the B-cell response. Immunology 2009. 128: 311-323.
31. Flo, T. H., Halaas, O., Torp, S., Ryan, L., Lien, E., Dybdahl, B., Sundan, A. et al., Differential expression of Toll-like receptor 2 in human cells. J. Leukoc. Biol. 2001. 69: 474-481.
32. Dasari, P., Nicholson, I. C., Hodge, G., Dandie, G. W. and Zola, H., Expression of toll-like receptors on B lymphocytes. Cell. Immunol. 2005. 236: 140-145.
33. Meyer-Bahlburg, A. and Rawlings, D. J., Differential impact of Toll-like receptor signaling on distinct B cell subpopulations. Front. Biosci. 2012. 17: 1499-1516.
34. Chang, Z. L., Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm. Res. 2010. 59: 791-808.
35. Corthals, S. L., Wynne, K., She, K., Shimizu, H., Curman, D., Garbutt, K. and Reid, G. S. D., Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 2006. 132: 452-458.
36. Jin, M. S., Kim, S. E., Heo, J. Y., Lee, M. E., Kim, H. M., Paik, S.-G., Lee, H. et al., Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007. 130: 1071-1082.
37. Kang, J. Y., Nan, X., Jin, M. S., Youn, S.-J., Ryu, Y. H., Mah, S., Han, S. H. et al., Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009. 31: 873-884.
38. Iwasaki, A. and Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. 5: 987-995.
39. Aliprantis, A., Yang, R. B., Mark, M. R., Suggett, S., Devaux, B., Radolf, J. D., Klimpel, G. R. et al., Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999. 285: 736-739.
40. Into, T., Kiura, K., Yasuda, M., Kataoka, H., Inoue, N., Hasebe, A., Takeda, K. et al., Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-κB activation. Cell. Microbiol. 2004. 6: 187-199.
41. Aliprantis, A. O., Yang, R. B., Weiss, D. S., Godowski, P. and Zychlinsky, A., The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. 2000. 19: 3325-3336.
42. Horng, T., Barton, G. M., Flavell, R. A. and Medzhitov, R., The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002. 420: 329-333.
43. O'Neill, L. A. J. and Bowie, A. G., The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007. 7: 353-364.
44. Santos-Sierra, S., Deshmukh, S. D., Kalnitski, J., Küenzi, P., Wymann, M. P., Golenbock, D. T. and Henneke, P., Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J. 2009. 28: 2018-2027.
45. Johnson, G. and Lapadat, R., Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002. 298: 1911-1913.
46. Matsuzawa, A. and Ichijo, H., Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1. J. Biochem. 2001. 130: 1-8.
47. Shi, Y., White, D., He, L., Miller, R. L. and Spaner, D. E., Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 2007. 67: 1823-1831.
48. Fonte, E., Apollonio, B., Scarfò, L., Ranghetti, P., Fazi, C., Ghia, P. and Caligaris-Cappio, F. et al., In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin. Cancer Res. 2013. 19: 367-379.
49. Abdi, J., Mutis, T., Garssen, J. and Redegeld, F., Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells. Blood Cancer J. 2013. 3: e119.
50. Rehli, M., Of mice and men: species variations of Toll-like receptor expression. Trends Immunol. 2002. 23: 375-378.
51. Werling, D., Jann, O. C., Offord, V., Glass, E. J. and Coffey, T. J., Variation matters: TLR structure and species-specific pathogen recognition. Trends Immunol. 2009. 30: 124-130.
52. Haehnel, V., Schwarzfischer, L., Fenton, M. J. and Rehli, M., Transcriptional regulation of the human Toll-like receptor 2 gene in monocytes and macrophages. J. Immunol. 2002. 168: 5629-5637.
53. Yu, L., Wang, L. and Chen, S., Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim. Biophys. Acta. 2013. 1835: 144-154.
54. Pradere, J.-P., Dapito, D. H. and Schwabe, R. F., The Yin and Yang of Toll-like receptors in cancer. Oncogene 2014. 33: 3485-3495.
55. Blander, J. M. and Sander, L. E., Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 2012. 12: 215-225.
56. Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H. and Xiong, H., TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008. 27: 218-224.
57. Shingu, K., Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung. Am. J. Respir. Cell Mol. Biol. 2003. 28: 316-321.
58. Murata, M., Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci. 2008. 99: 1435-1440.
59. Oldford, S. A., Haidl, I. D., Howatt, M. A., Leiva, C. A., Johnston, B. and Marshall, J. S., A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 2010. 185: 7067-7076.
60. Zhang, G., Chen, F., Cao, Y., Johnson, B. and See, W. A., HMGB1 release by urothelial carcinoma cells is required for the in vivo anti-tumor response to BCG. J. Urol. 2013. 189: 1541-1546.
61. Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L. et al., Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res. 2007. 67: 4346-4352.
62. Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L. et al., Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009. 457: 102-106.
63. Xie, W., Huang, Y., Xie, W., Guo, A. and Wu, W., Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting Toll-like receptor 2 in the cancer cells. PLoS One 2010. 5: e10850.
64. Yamazaki, S., Okada, K., Maruyama, A., Matsumoto, M., Yagita, H. and Seya, T., TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 2011. 6: e18833.
65. Shcheblyakov, D. V., Logunov, D. Y., Rakovskaya, I. V., Shmarov, M. M., Naroditsky, B. S. and Ginzburg, A. L., Triggering of Toll-like receptor-2 in mouse myelomonocytic leukaemia cells WEHI-3B leads to the suppression of apoptosis and promotes tumor progression in vivo. Acta Naturae 2011. 3: 83-93.
66. Van Bergenhenegouwen, J., Plantinga, T. S., Joosten, L. A. B., Netea, M. G., Folkerts, G., Kraneveld, A. D., Garssen, J. et al., TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J. Leukoc. Biol. 2013. 94: 885-902.
67. Yamamoto, M., Sato, S., Hemmi, H. and Sanjo, H., Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002. 420: 324-329.
68. Kucharczak, J., Simmons, M. J., Fan, Y. and Gélinas, C., To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003. 22: 8961-8982.
69. Novikova, L., Czymmeck, N., Deuretzbacher, A., Buck, F., Richter, K., Weber, A. N. R., Aepfelbacher, M. et al., Cell death triggered by Yersinia enterocolitica identifies processing of the proinflammatory signal adapter MyD88 as a general event in the execution of apoptosis. J. Immunol. 2014. 192: 1209-1219.
70. O'Neill, L., Wanted: a molecular basis for specificity in toll-like receptor signal transduction. Mol. Cell. 2002. 3: 969-971.
71. Berg, L. J., Strength of T cell receptor signaling strikes again. Immunity 2009. 31: 529-531.
72. Nolte, M. A., van Olffen, R. W., vanGisbergen, K. P. J. M. and vanLier, R. A. W., Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 2009. 229: 216-231.
73. Lechouane, F., Bonaud, A., Delpy, L., Casola, S., Oruc, Z., Chemin, G., Cogné, M. et al., B-cell receptor signal strength influences terminal differentiation. Eur. J. Immunol. 2013. 43: 619-628.
74. Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M. et al., Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012. 19: 107-120.
75. Salaun, B., Romero, P. and Lebecque, S., Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur. J. Immunol. 2007. 37: 3311-3318.
76. Shishodia, S. and Aggarwal, B. B., Nuclear factor-kappaB activation: a question of life or death. J. Biochem. Mol. Biol. 2002. 35: 28-40.
77. Dutta, J., Fan, Y., Gupta, N., Fan, G. and Gélinas, C., Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006. 25: 6800-6816.
78. Rahman, M. M. and McFadden, G., Modulation of NF-κB signalling by microbial pathogens. Nat. Rev. Microbiol. 2011. 9: 291-306.
79. Li, X., Jiang, S. and Tapping, R. I., Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010. 49: 1-9.
80. Sen, R. and Smale, S. T., Selectivity of the NF-{kappa}B response. Cold Spring Harb. Perspect. Biol. 2010. 2: a000257.
81. Hoffmann, A., Levchenko, A., Scott, M. L. and Baltimore, D., The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002. 298: 1241-1245.
82. Bode, K. A., Schmitz, F., Vargas, L., Heeg, K. and Dalpke, A. H., Kinetic of RelA activation controls magnitude of TLR-mediated IL-12p40 induction. J. Immunol. 2009. 182: 2176-2184.
83. Ha, T., Lu, C., Liu, L., Hua, F., Hu, Y., Kelley, J., Singh, K. et al., TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide 3-kinase-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 2010. 298: H984-H991.
84. Lu, C., Liu, L., Chen, Y., Ha, T., Kelley, J., Schweitzer, J., Kalbfleisch, J. H. et al., TLR2 ligand induces protection against cerebral ischemia/reperfusion injury via activation of phosphoinositide 3-kinase/Akt signaling. J. Immunol. 2011. 187: 1458-1466.
85. Meng, X., Martinez, M. A., Raymond-Stintz, M. A., Winter, S. S. and Wilson, B. S., IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts. Br. J. Haematol. 2010. 148: 487-490.
86. Zanotto-Filho, A., Delgado-Cañedo, A., Schröder, R., Becker, M., Klamt F and Moreira J. C. F. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett. 2010. 288: 192-203.
87. Nakagami, H. and Morishita, R., Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001. 50: 1472-1481.
88. Into, T. and Shibata, K.-I., Apoptosis signal-regulating kinase 1-mediated sustained p38 mitogen-activated protein kinase activation regulates mycoplasmal lipoprotein- and staphylococcal peptidoglycan-triggered Toll-like receptor 2 signalling pathways. Cell. Microbiol. 2005. 7: 1305-1317.
89. Raetz, E. A. and Bhatla, T., Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematol. Am. Soc. Hematol. Educ. Program. 2012. 2012: 129-136.
90. Bhojwani, D. and Pui, C.-H., Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013. 14: e205-e217.
91. Locatelli, F., Schrappe, M., Bernardo, M. E. and Rutella, S., How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012. 120: 2807-2816.
92. Jacoby, E., Chien, C. D. and Fry, T. J., Murine models of acute leukemia: important tools in current pediatric leukemia research. Front. Oncol. 2014. 4: 95.